{"product_id":"annexonbio-pestle-analysis","title":"Annexon PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock strategic clarity with our Annexon PESTLE Analysis—three to five concise perspectives on political, economic, social, technological, legal, and environmental forces shaping its future. Ideal for investors and strategists, this brief shows the key risks and opportunities; purchase the full report for exhaustive, actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS and EU regulatory priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS and EU regulators now prioritize clear clinical benefit in neurodegenerative therapies, influencing review speed and trial-design expectations and contributing to historically high failure rates in the field (≈99% for Alzheimer’s candidates). \u003c\/p\u003e\n\u003cp\u003eShifts toward hard clinical endpoints over surrogate biomarkers can add years to development timelines; lecanemab received accelerated approval in 2023, showing policy can flex when evidence is robust.\u003c\/p\u003e\n\u003cp\u003eProactive FDA\/EMA engagement on complement biology and C1q-specific guidance is pivotal for trial acceptability and potential use of expedited pathways like Breakthrough or Accelerated Approval if unmet-need evidence is strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment funding and public–private consortia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNIH’s annual budget is roughly $50 billion and long-running programs like the BRAIN Initiative have mobilized over $1 billion to date; Horizon Europe totals €95.5 billion for 2021–2027, supporting neurodegeneration consortia that de-risk early biomarker work. Participation in NIH\/EU consortia can shape outcome-measure standards for complement-mediated disease and expand datasets Annexon can access. Political backing for neuroscience moonshots increases data and funding, but cycles and priorities can shift with administrations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing and access agendas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure on specialty drug costs shapes payer behavior and launch strategies; specialty medicines accounted for about 54% of U.S. drug spend in 2023 (IQVIA), driving scrutiny.\u003c\/p\u003e\n\u003cp\u003ePolicies like the U.S. Inflation Reduction Act enabling Medicare price negotiation from 2026 and reference pricing\/HTA (NICE thresholds ~£20–30k\/QALY) compress biologic margins.\u003c\/p\u003e\n\u003cp\u003eOrphan status (7-year U.S. exclusivity) can soften impact but requires robust value dossiers; early health-economics planning for HTA submissions is politically strategic.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply-chain stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTensions affecting biologics inputs, sterile consumables, and cold-chain logistics have extended procurement lead times to roughly 9–18 months in 2023–24, risking clinical and commercial timelines. Export controls and tariffs on advanced manufacturing equipment increase capex and can add months to installation schedules. Political incentives for onshoring (recent national grants and tax credits) can offset risk but require sizable upfront investment; diversified sourcing is a strategic hedge.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLead-time risk: 9–18 months\u003c\/li\u003e\n\u003cli\u003eCapex pressure: higher due to export controls\/tariffs\u003c\/li\u003e\n\u003cli\u003eMitigation: onshoring incentives vs diversified suppliers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth policy focus on real-world evidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernments increasingly tie coverage and post-market obligations to real-world data, requiring early-access dossiers to include ongoing evidence-generation; FDA's RWE Framework (2018) and EMA registry guidance (2022) exemplify this trend, while the EU European Health Data Space enters implementation in 2025, strengthening data infrastructure mandates that affect trial follow-up design. Annexon must budget for registries and long-term outcomes collection to meet these obligations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRWE frameworks: FDA 2018; EMA 2022\u003c\/li\u003e\n\u003cli\u003eEHDS implementation: 2025\u003c\/li\u003e\n\u003cli\u003eImplication: plan registries, long-term follow-up\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory scrutiny, RWE rules and Medicare negotiation to squeeze neurodegeneration returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegulators demand clear clinical benefit in neurodegeneration (Alzheimer’s failure ≈99%), slowing approvals; lecanemab’s 2023 accelerated approval shows flexibility. NIH budget ≈$50B (2024) and Horizon Europe €95.5B (2021–27) boost consortia and biomarker work; EHDS implementation 2025 increases RWE obligations. Specialty drugs =54% US drug spend (2023); IRA enables Medicare negotiation from 2026, compressing margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer’s failure rate\u003c\/td\u003e\n\u003ctd\u003e≈99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH budget\u003c\/td\u003e\n\u003ctd\u003e$50B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon Europe\u003c\/td\u003e\n\u003ctd\u003e€95.5B (2021–27)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty drug spend US (2023)\u003c\/td\u003e\n\u003ctd\u003e54%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare negotiation\u003c\/td\u003e\n\u003ctd\u003efrom 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely influence Annexon across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed trends and industry-specific subpoints to highlight risks, opportunities, and strategic implications for executives, investors, and advisors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary for Annexon that can be dropped into presentations, edited with notes per region or business line, and easily shared for quick team alignment—simplifying external risk discussions and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market cyclicality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical-stage biotech valuations and financing windows are highly cyclical, with public and private raises thinning in risk-off periods and expanding in risk-on windows. Higher interest rates (federal funds near 5.25% mid‑2025) compress equity appetites, shortening typical cash runways to roughly 12–24 months and increasing dilution risk. Milestone-based partnerships, often including upfronts and milestone tranches \u0026gt;$100m, can bridge lean periods. Prudent cash burn tied to upcoming value inflections is therefore critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer willingness-to-pay for neuro therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePayers intensely scrutinize budget impact of high-cost biologics as specialty drugs now comprise roughly half of US drug spend; cost-effectiveness standards (ICER $100,000–$150,000\/QALY) push sponsors to show clear functional gains and reduced caregiver costs to justify prices. Companion diagnostics raise upfront costs but can lower cost per responder and strengthen value dossiers; early pricing and access models guide indication sequencing and launch strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing scale-up economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiologic CMC scale-up requires steep fixed capital (typical new mammalian plants cost $100–300M) plus validation and regulatory costs often in the $10–30M range, driving high upfront breakeven. Outsourcing to CDMOs avoids that capex but shifts economics to higher variable COGS, potentially compressing launch gross margin by single- to low-double-digit percentage points. Yield gains are highly levered—e.g., a 20–30% titer lift can cut COGS roughly proportionally and materially boost gross margin at launch. Dual sourcing typically increases unit cost by ~5–15% while significantly improving supply security and reducing outage risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency and global launch sequencing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFX swings materially affect trial budgets and ex-US revenue translation; currency volatility has driven +\/-10% P\u0026amp;L impact for biotech launches in recent cycles.\u003c\/p\u003e\n\u003cp\u003ePrioritizing higher-price markets (US prices ~2.5x EU on avg) speeds cash generation but raises parallel-trade exposure across EU markets.\u003c\/p\u003e\n\u003cp\u003eEconomic strain raises patient co-pay support needs — US specialty patients often face thousands USD OOP annually — and sequencing tied to HTA timelines (NICE ~12 months; AMNOG first-year pricing) can smooth cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX impact: +\/-10%\u003c\/li\u003e\n\u003cli\u003eUS vs EU price: ~2.5x\u003c\/li\u003e\n\u003cli\u003eHTA timing: NICE ~12 months\u003c\/li\u003e\n\u003cli\u003ePatient OOP: thousands USD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eM\u0026amp;A and partnering landscape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarger pharmas continue prioritizing neuro and immunology assets, driving competitive bidding that lifted median upfronts in top-stage deals to around $150–250m in 2024 while pushing acquirers to demand stronger proof-of-concept data. Royalty-plus-option structures are increasingly used to preserve upside and extend runway for developers. Macro slowdowns in 2024–H1 2025 delayed closings despite strategic fits, compressing deal volumes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eTrend: big pharmas chasing neuro\/immunology\u003c\/li\u003e\n\u003cli\u003eFinance: median upfronts ~150–250m (2024)\u003c\/li\u003e\n\u003cli\u003eStructure: royalty\/option preserves upside\u003c\/li\u003e\n\u003cli\u003eMacro: 2024–H1 2025 slowdown delayed deals\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory scrutiny, RWE rules and Medicare negotiation to squeeze neurodegeneration returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiotech funding is cyclical; higher rates (fed funds ~5.25% mid‑2025) shorten equity runways to ~12–24 months and raise dilution risk. Payers demand clear value (ICER ~$100–150k\/QALY) as specialty drugs drive ~50% of US drug spend, pushing pricing\/launch strategies. CMC capex ($100–300M plants) and CDMO tradeoffs shape margins; FX and HTA timing (NICE ~12 months) materially affect cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds\u003c\/td\u003e\n\u003ctd\u003e~5.25% (mid‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash runway\u003c\/td\u003e\n\u003ctd\u003e12–24 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS vs EU price\u003c\/td\u003e\n\u003ctd\u003e~2.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian upfronts (2024)\u003c\/td\u003e\n\u003ctd\u003e$150–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX impact\u003c\/td\u003e\n\u003ctd\u003e±10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAnnexon PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the exact Annexon PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use. No placeholders or teasers; the content, layout, and structure are identical to the downloadable file delivered at checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162781299065,"sku":"annexonbio-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/annexonbio-pestle-analysis.png?v=1762708500","url":"https:\/\/portersfiveforce.com\/products\/annexonbio-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}